Can a new drug boost the fight against esophageal cancer?
NCT ID NCT07751341
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to 75 with this type of cancer that cannot be removed by surgery or has spread. The goal is to see if adding SHR-9839 improves tumor shrinkage and overall survival compared to the current standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-9839 (an experimental drug) given alone or with chemotherapy (paclitaxel and cisplatin) plus adebrelimab (an immunotherapy)
- What this could lead to
- If successful, this could lead to a new treatment option that helps control advanced esophageal cancer, potentially improving response rates and survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The drug may cause side effects or may not be more effective than current treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 1000142, China
-
The First Affiliated Hospital Of Zhengzhou University
Zhengzhou, Henan, 450052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a flexible dosing schedule improve esophageal cancer treatment?
- New drug cocktail targets Hard-to-Treat cancers
- New drug YL201 takes on tough esophageal cancer
- Smart MRI tailors cancer therapy for better outcomes
- New drug cocktail aims to fight tough esophageal cancer
- New hope for tough esophageal cancer: drug combo targets gene mutations